Skip to main content
OpenTrials
Completed

NCT Number: NCT03881787

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

Background Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise. Surgery-based, combined with chemotherapy, radiotherapy comprehensive treatment, is the main treatment of colorectal cancer. Surgical resection has been recognized as the primary treatment of colorectal cancer. However, due to the majority of patients already advanced at the time of diagnosis, some difficulties are brought to radical surgery. Therefore, the importance of chemotherapy for colorectal cancer gradually been clinically recognized, But rarely survive more than 18 months." In addition to chemotherapy, there is now a more ideal model of cancer treatment- molecular targeted therapies, including monoclonal antibody drugs such as cetuximab, as well as small molecule tyrosine kinases Inhibitors gefitinib and so on. Molecular targeted drugs make use of the difference in molecular biology between tumor cells and normal cells. Targeting drugs to tumor cells and inhibiting the growth and proliferation of the cells can achieve the therapeutic effect, which has the advantages of high specificity and low adverse reaction. The bio-targeted drug cetuximab is the first drug approved to marketed as an epidermal growth factor receptor (EGFR)-targeting immunoglobulin 1（IgG1）monoclonal antibody. Cetuximab, either monotherapy or combined radiotherapy and chemotherapy, can exert excellent anti-tumor activity in EGFR-positive malignant tumors and can significantly enhance the efficacy of radiotherapy and chemotherapy.

Reference to cetuximab injection, guilin sanjin Co., Ltd. and dragonboat Co., Ltd. jointly developed a recombinant anti-EGFR human mouse chimeric monoclonal antibody (R & D code: CDP1).The primary structure of CDP1 is exactly the same with cetuximab, the higher structure and Physical and chemical properties and cetuximab are highly similar. Pharmacodynamic activity in vivo and in vitro, pharmacokinetic characteristics and toxicological reactions are also similar to cetuximab. CDP1 selected with cetuximab consistent formulations, prescriptions, specifications.

CDP1 was approved by China Food and Drug Administration (No. 2016L06884) in August 2016 for clinical studies. According to the contents of the document and guidelines for biological analogs, the clinical pharmacokinetic and clinical effectiveness comparison tests of CDP1 and the safety and immunogenicity assessment are planned.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Shanghai Public Health Clinical Center, Shanghai, Shanghai Municipality, China

Loading trial locations.

About this study

OBJECTIVES:

Primary:

To compare the pharmacokinetic characteristics of a single dose between CDP1 and the original drug Erbitux in healthy volunteers.

Secondary :

To compare the safety and immunogenic characteristics of the single dose between CDP1 and the original drug Erbitux in healthy volunteers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult volunteers participate in clinical trials voluntarily and sign informed consent.
  • Age 18 ~ 45 (inclusive) years , male.
  • The body weight is not less than 50 kg, and the body mass index is between 18.5 and 26 (including both ends).
  • Good health, no heart, liver, kidney or other acute or chronic digestive tract diseases, respiratory diseases, blood, endocrine, nervous, mental and other systemic diseases.
  • Physical examination, vital signs, blood routine, urine routine, blood biochemistry, electrocardiogram and chest X-ray examination are all normal, or the abnormal results of the examination are not clinically meaningful by the investigator.
  • Agree to avoid spouse pregnancy during the trial period and within 6 months after the end of the administration.

Exclusion criteria

  • Allergic constitution, those who are allergic to the test drug ingredients or have a history of allergies to any drug or food or a history of pollen allergy; those with abnormal serum immunoglobulin E (IgE) (more than 3 times higher than the upper limit of normal).
  • Anti-drug antibody (ADA) positive.
  • Infections currently in need of clinical treatment.
  • HBsAg, HBeAg, HCV-Ab, HIV-Ab or TP-Ab positive.
  • Upon inquiry, there is a clear current medical history of the central nervous system, cardiovascular system, kidney, liver, digestive system, respiratory system, metabolic system or other significant diseases.
  • Upon inquiry, a person with a history of mental illness.
  • Upon inquiry, there is a history of cancer and it is judged by the investigator that it is not suitable for participation.
  • According to the investigator's judgment, the investigator believes that it is not suitable for the participants in this clinical trial for various reasons.

Treatment and study plan

anti-EGFR monoclonal antibody

Drug

Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection

Other names: CDP1

Cetuximab injection

Drug

Cetuximab injection

Other names: Erbitux

Primary outcomes

  1. Pharmacokinetic Parameters: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Infusion

    Time frame: Up to 22 Days

    AUC(0-t) for CDP1

Secondary outcomes

  1. Pharmacokinetic parameters: Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUC0-00) After Infusion

    Time frame: Up to 22 Days

    Pharmacokinetic parameters: AUC(0-00) for CDP1

  2. Pharmacokinetic parameters: Observed Maximum Serum Concentration (Cmax) of CDP1 After Infusion

    Time frame: Up to 22 Days

    Pharmacokinetic parameters Cmax for CDP1

  3. Pharmacokinetic parameters: Mean Residence Time of Drug in the Body (MRT) of CDP1 After Infusion

    Time frame: Up to 22 Days

    Pharmacokinetic parameters MRT for CDP1

  4. Pharmacokinetic parameters: Apparent Terminal Half-life (t1/2) of CDP1 After Infusion

    Time frame: Up to 22 Days

    Pharmacokinetic parameters T1/2 for CDP1

  5. Pharmacokinetic parameters: Total Body Clearance of Drug From Serum (CL) After Infusion

    Time frame: Up to 22 Days

    Pharmacokinetic parameters CL for CDP1

  6. Vital signs: Blood pressure

    Time frame: Up to 29 Days

    Vital signs: Blood pressure

  7. Vital signs: Pulse rate

    Time frame: Up to 29 Days

    Vital signs: Pulse rate

  8. Vital signs: Respiratory rate

    Time frame: Up to 29 Days

    Vital signs: Respiratory rate

  9. Physical examination: Weigh

    Time frame: Up to 29 Days

    Physical examination: Weigh

  10. Frequency of adverse events (AE)

    Time frame: Up to 29 Days

    Frequency of adverse events (AE)

  11. Immunogenicity indicators: Anti-drug antibodies (ADA)

    Time frame: Up to 29 Days

    Immunogenicity indicators: Anti-drug antibodies (ADA)

  12. Immunogenicity indicators: neutralizing antibodies

    Time frame: Up to 29 Days

    Immunogenicity indicators: neutralizing antibodies

Sponsors and collaborators

Lead sponsor

Dragonboat Biopharmaceutical Company Limited

Industry

Collaborators

  • Shanghai Public Health Clinical Center
  • West China Hospital

Registry information

Official study title

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) to Healthy Volunteers Compared to Erbitux

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Mar 20, 2019
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.